Anti-Ro antibody test results can be used to monitor disease progression and therapeutic outcomes; in patients with RA, positive anti-Ro test results (Ro60 or Ro52 not specified) were associated with treatment resistance to infliximab, but not with tocilizumab and/or abatacept [121]. Here, TRIM21 is linked to rheumatoid arthritis.